Navigation Links
Lentigen Corporation Announces Relocation to New Facility
Date:9/9/2008

GAITHERSBURG, Md., Sept. 9 /PRNewswire/ -- Lentigen Corporation announced today that it has relocated its corporate headquarters, research labs and manufacturing from the University of Maryland Baltimore County TechCenter, to 910 Clopper Road, Suite 200 South Building, Gaithersburg, MD 20878 (Tel: 301.527.4200).

Located along Maryland's I-270 technology corridor, the almost 26,000 square-foot facility will accommodate Lentigen's future growth needs as the leading developer and manufacturer of lentiviral vectors (LVs) and proteins for a wide range of clinical and research applications. Two self-contained suites measuring 4,900 square feet will allow the simultaneous production of both LVs and proteins in compliance with FDA-regulated current good manufacturing practices (cGMP).

"We appreciated the opportunity afforded to grow our company at the TechCenter, but the move to our new facility is a significant step forward in our evolution as a biotech company," stated Tim Ravenscroft, Lentigen's CEO. "The new facility provides an opportunity to expand our research programs. More importantly, the addition of the cGMP manufacturing suites will allow us to manage our programs from the labs through manufacturing to the clinic. We plan to manufacture lentiviral products for clinical trials during 2009 and we will have capacity to handle manufacturing projects for collaborators as the market for lentiviral products expands."

About Lentigen Corporation

Lentigen Corporation is a privately owned biotechnology company focused on the development of lentiviral vector technology for a wide range of therapeutic, vaccine, and research applications in biotechnology and medicine. Lentiviral vectors are the most efficient vehicles for the delivery of genes or gene silencing sequences stably into cells. Lentigen is a highly collaborative company, co-developing lentiviral vector-based products across a broad spectrum of bench to clinical applications. Partnerships include The National Institutes of Health, The University of Pennsylvania, Invitrogen, ThermoFisher Scientific and The U.S. Army. For further information, visit http://www.lentigen.com

Contact:

Richard Lewis Communications, Inc.

212-827-0020

Cecelia Heer - Investors

cheer@rlcinc.com

Megan Dubrowski - Media

mdubrowski@rlcinc.com


'/>"/>
SOURCE Lentigen Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. VIRxSYS and Lentigen Announce Litigation Settlement
2. Lentigen Appoints Tim Ravenscroft as Chief Executive Officer
3. Lentigen to Move Headquarters and Manufacturing to Gaithersburg
4. Lentigen Corporation Announces Exclusive Licensing Agreement With Case Western Reserve University to Develop Novel Stem-Cell Therapy for Brain Cancer
5. Lentigen Licenses Fundamental Lentiviral Vector Technology Patent From the University of Cambridge
6. Lentigen Corporation Receives Four Research Grants From the National Institutes of Health
7. Lentigen Appoints Jim Meade as Vice President of Corporate Development
8. Memry Corporation Announces Preliminary Fiscal Fourth Quarter and 2007 Revenue
9. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
10. AGA Medical Corporation Receives FDA and CE Mark Approvals for the AMPLATZER Vascular Plug II
11. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... 23, 2016 /PRNewswire/ - FACIT has announced the ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or ... of a portfolio of first-in-class WDR5 inhibitors for ... as WDR5 represent an exciting class of therapies, ... medicine for cancer patients. Substantial advances have been ...
(Date:6/23/2016)... 2016  The Biodesign Challenge (BDC), a university competition ... harness living systems and biotechnology, announced its winning teams ... New York City . The ... projects at MoMA,s Celeste Bartos Theater during the daylong ... senior curator of architecture and design, and Suzanne ...
(Date:6/23/2016)... Ky. , June 23, 2016 ... two Phase 1 clinical trials of its complement ... placebo-controlled, single and multiple ascending dose studies designed ... pharmacodynamics (PD) of subcutaneous injection in healthy adult ... subcutaneously (SC) either as a single dose (ranging ...
(Date:6/23/2016)... ... June 23, 2016 , ... Regulatory Compliance Associates® Inc. (RCA), ... free webinar on Performing Quality Investigations: Getting to Root Cause. ... no charge. , Incomplete investigations are still a major concern to the Regulatory ...
Breaking Biology Technology:
(Date:6/7/2016)... , June 7, 2016  Syngrafii Inc. ... a business relationship that includes integrating Syngrafii,s patented ... branch project. This collaboration will result in greater ... the credit union, while maintaining existing document workflow ... http://photos.prnewswire.com/prnh/20160606/375871LOGO ...
(Date:6/1/2016)... June 1, 2016 Favorable Government ... Administration and Criminal Identification to Boost Global Biometrics System ... released TechSci Research report, " Global Biometrics Market ... Forecast and Opportunities, 2011 - 2021", the global biometrics ... 2021, on account of growing security concerns across various ...
(Date:5/9/2016)... 2016 Elevay is currently known ... freedom for high net worth professionals seeking travel for ... connected world, there is still no substitute for a ... sealing your deal with a firm handshake. This is ... advantage of citizenship via investment programs like those offered ...
Breaking Biology News(10 mins):